Inflammatory Bowel Diseases: New Developments and StandardsW.E. Fleig Springer Science & Business Media, 30 nov 1995 - 326 páginas Falk Symposium No. 82, held in Halle, Germany, November 1994, focuses on the advances made in understanding the aetiology and pathogenesis of inflammatory bowel disease (IBD). Sections of this book, the Proceedings of the conference, are devoted to extraintestinal manifestations, cancer development, IBD in the context of pregnancy, and the assessment of disease activity, prognosis and quality of life. The second half of the book is devoted to the discussion of standards and new developments in diagnosis, conservative management and surgery. Audience: All clinicians and basic scientists working in the field of IBD. |
Índice
Genetic susceptibilities major aetiological risk factors for IBD | 3 |
Psychosocial factors | 14 |
Microbial factors in the pathogenesis of IBD | 23 |
Crohn disease a virustriggered vasculitis? | 35 |
The role of the cellular immune response in the pathogenesis of IBD | 42 |
Soluble inflammatory mediators | 50 |
Role of nitric oxide and free radicals in the pathogenesis of IBD | 66 |
EXTRAINTESTINAL MANIFESTATIONS AND SPECIAL PROBLEMS IN IBD | 77 |
Conventional radiology CT and MRI in IBD | 163 |
Diagnosis of perianal fistula and abscess | 166 |
Laboratory tests in IBD which and when? | 173 |
STANDARDS AND NEW DEVELOPMENTS IN MEDICAL TREATMENT | 181 |
Sulphasalazine mesalazine and other 5ASA derivatives | 183 |
Old and new steroids | 193 |
An update of immunosuppressive therapy in IBD | 225 |
Nutrition and diet | 232 |
Enterogenic arthropathy | 79 |
The skin in chronic IBD | 94 |
Pregnancy in CIBD a nonproblem? | 101 |
The risk of cancer in IBD a plea for surveillance? | 111 |
MEASURES OF DISEASE ACTIVITY PROGNOSIS AND QUALITY OF LIFE | 119 |
Measuring disease activity do we need new indices? | 121 |
Prognostic indicators for remission relapse and postoperative recurrence in IBD | 126 |
Quality of life in IBD does it reflect activity of disease? | 134 |
STANDARDS AND NEW DEVELOPMENTS IN DIAGNOSIS | 145 |
How much endoscopy and when points to be considered in diagnosis and followup | 147 |
IBD diagnostic relevance of abdominal sonography | 153 |
Efficacy of psychosomatic therapy in Crohn disease | 242 |
Treatment strategy in chronic active Crohn disease | 254 |
STANDARDS AND NEW DEVELOPMENTS IN SURGICAL THERAPY | 257 |
Surgery in ulcerative colitis | 259 |
Pros and cons of the ileoanal pouch | 271 |
Current standards in surgery for Crohn disease | 280 |
Nonresective surgery for Crohn disease | 289 |
Optimized treatment of fistulae in Crohn disease | 297 |
Medical treatment for prevention of postoperative recurrence of Crohn disease? | 311 |
| 317 | |
Términos y frases comunes
5-aminosalicylic acid abdominal abscesses active Crohn disease active disease acute anastomosis antibodies antigens arthritis assessment associated azathioprine bacterial biopsy budesonide CDAI cells CIBD Clin clinical colectomy colonoscopy colorectal cancer complications corticosteroids Crohn disease cyclosporin cytokines developed diagnosis diarrhoea disease activity distal dose drug dysplasia effects endoscopic enemas extraintestinal factors faecal diversion Figure fistulae Gastroenterology gastrointestinal gene genetic glucocorticoids ileal ileoanal ileostomy ileum increased indices infection inflammation inflammatory bowel disease interleukin-1 intestinal involvement lamina propria Lancet Lennard-Jones lesions luminal lymphocytes mesalazine mucosal normal oral parameters pathogenesis patients with active patients with Crohn patients with inflammatory patients with ulcerative perianal placebo postoperative pouch prednisolone pregnancy proctocolectomy protein psychosocial psychotherapy receptor rectal recurrence relapse remission resection risk Scand J Gastroenterol serum side-effects small bowel steroids strictureplasty sulphasalazine Surg surgery surveillance symptoms Table therapeutic therapy tion tissue treated UC and CD ulcerative colitis